Antiviral resistance in influenza viruses;Resistens hos influensavirus

Tidsskrift for den Norske Laegeforening

Volumn 128, Issue 22, 2008, Pages 2601-2606

  Hungnes, Olav ^a   Dudman, Susanne Gjeruldsen ^a  

^a Avdeling for Virologi   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ENZYME INHIBITOR; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; SIALIDASE;

ANIMAL; ANTIVIRAL RESISTANCE; ARTICLE; AVIAN INFLUENZA; BIRD; DISEASE TRANSMISSION; DRUG ANTAGONISM; DRUG EFFECT; EPIDEMIC; GENETICS; HUMAN; INFECTION CONTROL; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INFLUENZA VIRUS C; INTERNATIONAL COOPERATION; ORTHOMYXOVIRUS; VIROLOGY; ZOONOSIS;

ANIMALS; ANTIVIRAL AGENTS; BIRDS; COMMUNICABLE DISEASE CONTROL; DISEASE OUTBREAKS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA IN BIRDS; INFLUENZA, HUMAN; INFLUENZAVIRUS C; INTERNATIONAL COOPERATION; NEURAMINIDASE; ORTHOMYXOVIRIDAE; VIRAL MATRIX PROTEINS; ZOONOSES;

EID: 56749161484     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Nasjonalt folkehelseinstitutt. Influensa. www.fhi.no/influensa (10.5.2008).
2. Nasjonal beredskapsplan for pandemisk influensa. Revidert utg. Oslo: Helsedepartementet, 2003.
3. Hayden FG, Pavia AT. Antiviral management of seasonal and pandemic influenza. J Infect Dis 2006; 194 (suppl 2): 119-26.
4. Jefferson T, Demicheli V, Di Pietrantonj C et al. Amantadine and rimantadine for influenza A in adults. Cochrane Database Syst Rev 2006; nr. 2: CD001169.
5. Stouffer AL, Acharya R, Salom D et al. Structural basis for the function and inhibition of an influenza virus proton channel. Nature 2008; 451: 596-9.
6. Jefferson T, Demicheli V, Rivetti D et al. Antivirals for influenza in healthy adults: systematic review. Lancet 2006; 367: 303-13.
7. Monto AS, Robinson DP, Herlocher ML et al. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999; 282: 31-5.
8. Reseptregisteret. www.reseptregisteret.no (10.5.2008).
9. McGeer A, Green KA, Plevneshi A et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007; 45: 1568-75.
10. Cochran KW, Maassab HF, Tsunoda A et al. Studies on the antiviral activity of amantadine hydrochloride. Ann NY Acad Sci 1965; 130: 432-9.
11. Hayden FG, Sperber SJ, Belshe RB et al. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother 1991; 35: 1741-7.
12. Hayden FG, Hay AJ. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol 1992; 176: 119-30.
13. Monto AS, McKimm-Breschkin JL, Macken C et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006; 50: 2395-402.
14. Reece PA. Neuraminidase inhibitor resistance in influenza viruses. J Med Virol 2007; 79: 1577-86.
15. Ison MG, Gubareva LV, Atmar RL et al. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis 2006; 193: 760-4.
16. Hayden FG, Belshe R, Villanueva C et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 2004; 189: 440-9.
17. Coen DM, Richman DD. Antiviral agents. I: Knipe DM, Howley PM, red. Field's virology. Philadelphia, PA: Lippincott Williams & Wilkins, 2007: 447-85.
18. Deyde VM, Xu X, Bright RA et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 2007; 196: 249-57.
19. Zambon M, Hayden FG. Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res 2001; 49: 147-56.
20. European surveillance network for vigilance against viral resistance (VIRGIL). www.virgil-net.org/ (10.5.2008).
21. Lackenby A, Hungnes O, Dudman SG et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill 2008; 13: pii 8026.
22. Ives JA, Carr JA, Mendel DB et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 2002; 55: 307-17.
23. Nasjonalt folkehelseinstitutt. Influensavirus i Norge resistent mot oseltamivir (Tamiflu). MSIS-rapport nr. 3/2008. www.fhi.no/artikler?id=67569 (10.5.2008).
24. European Centre for Disease Prevention and Control. Influenza. http://ecdc.europa.eu/Health_topics/influenza/Index.html (10.5.2008).
25. World Health Organization. Influenza A(H1N1) virus resistance to oseltamivir. www.who.int/csr/disease/influenza/h1n1_table/en/index.html (24.7.2008).
26. Schunemann HJ, Hill SR, Kakad M et al. WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis 2007; 7: 21-31.
27. Hurt AC, Selleck P, Komadina N et al. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res 2007; 73: 228-31.
28. McKimm-Breschkin J, Trivedi T, Hampson A et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 2003; 47: 2264-72.
29. Le QM, Kiso M, Someya K et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005; 437: 1108.
30. de Jong MD, Tran TT, Truong HK et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353: 2667-72.
31. Yen HL, Ilyushina NA, Salomon R et al. Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. J Virol 2007; 81: 12418-26.
32. Russell RJ, Haire LF, Stevens DJ et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006; 443: 45-9.
33. Sidwell RW, Barnard DL, Day CW et al. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother 2007; 51: 845-51.
34. Malakhov MP, Aschenbrenner LM, Smee DF et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 2006; 50: 1470-9.